Bafna Pharmaceuticals Limited (BAFNAPH) - Net Assets
Based on the latest financial reports, Bafna Pharmaceuticals Limited (BAFNAPH) has net assets worth Rs1.00 Billion INR (≈ $10.83 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs1.76 Billion ≈ $18.98 Million USD) and total liabilities (Rs753.88 Million ≈ $8.15 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Bafna Pharmaceuticals Limited (BAFNAPH) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs1.00 Billion |
| % of Total Assets | 57.05% |
| Annual Growth Rate | 16.23% |
| 5-Year Change | 61.62% |
| 10-Year Change | 137.81% |
| Growth Volatility | 60.71 |
Bafna Pharmaceuticals Limited - Net Assets Trend (2005–2026)
This chart illustrates how Bafna Pharmaceuticals Limited's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Bafna Pharmaceuticals Limited to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Bafna Pharmaceuticals Limited (2005–2026)
The table below shows the annual net assets of Bafna Pharmaceuticals Limited from 2005 to 2026. For live valuation and market cap data, see how much is Bafna Pharmaceuticals Limited worth.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | Rs1.00 Billion ≈ $10.83 Million |
+18.09% |
| 2025-03-31 | Rs848.07 Million ≈ $9.17 Million |
+4.91% |
| 2024-03-31 | Rs808.39 Million ≈ $8.74 Million |
+10.05% |
| 2023-03-31 | Rs734.55 Million ≈ $7.94 Million |
+18.54% |
| 2022-03-31 | Rs619.64 Million ≈ $6.70 Million |
+9.15% |
| 2021-03-31 | Rs567.71 Million ≈ $6.14 Million |
+10.89% |
| 2020-03-31 | Rs511.95 Million ≈ $5.54 Million |
+171.56% |
| 2019-03-31 | Rs188.52 Million ≈ $2.04 Million |
-49.33% |
| 2018-03-31 | Rs372.02 Million ≈ $4.02 Million |
-11.66% |
| 2017-03-31 | Rs421.12 Million ≈ $4.55 Million |
-26.85% |
| 2016-03-31 | Rs575.71 Million ≈ $6.23 Million |
-20.82% |
| 2015-03-31 | Rs727.13 Million ≈ $7.86 Million |
+4.25% |
| 2014-03-31 | Rs697.48 Million ≈ $7.54 Million |
+2.11% |
| 2013-03-31 | Rs683.04 Million ≈ $7.39 Million |
+5.71% |
| 2012-03-31 | Rs646.17 Million ≈ $6.99 Million |
+19.24% |
| 2011-03-31 | Rs541.89 Million ≈ $5.86 Million |
+32.15% |
| 2010-03-31 | Rs410.05 Million ≈ $4.43 Million |
+6.44% |
| 2009-03-31 | Rs385.23 Million ≈ $4.17 Million |
+224.96% |
| 2008-03-31 | Rs118.55 Million ≈ $1.28 Million |
+29.72% |
| 2007-03-31 | Rs91.39 Million ≈ $988.34K |
+60.95% |
| 2006-03-31 | Rs56.78 Million ≈ $614.05K |
+33.45% |
| 2005-03-31 | Rs42.55 Million ≈ $460.13K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bafna Pharmaceuticals Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rs236.56 Million | 24.60% |
| Other Components | Rs724.93 Million | 75.40% |
| Total Equity | Rs961.50 Million | 100.00% |
Bafna Pharmaceuticals Limited Competitors by Market Cap
The table below lists competitors of Bafna Pharmaceuticals Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Abnova Taiwan Corp
TW:4133
|
$39.49 Million |
|
Infrea AB
ST:INFREA
|
$39.52 Million |
|
The Beachbody Company, Inc.
NASDAQ:BODI
|
$39.53 Million |
|
BG Staffing Inc
NYSE:BGSF
|
$39.55 Million |
|
Globetronics Tech Bhd
KLSE:7022
|
$39.48 Million |
|
Gold Strike Resources Corp.
V:GSR
|
$39.47 Million |
|
Aviation Links Ltd
TA:AVIA
|
$39.46 Million |
|
German High Street Properties A/S Class B
CO:GERHSP
|
$39.45 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bafna Pharmaceuticals Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 848,065,000 to 961,495,000, a change of 113,430,000 (13.4%).
- Net income of 110,998,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 289,049,000.
- Other factors increased equity by 291,481,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs111.00 Million | +11.54% |
| Other Comprehensive Income | Rs-289.05 Million | -30.06% |
| Other Changes | Rs291.48 Million | +30.32% |
| Total Change | Rs- | 13.38% |
Book Value vs Market Value Analysis
This analysis compares Bafna Pharmaceuticals Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.80x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 15.29x to 3.80x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | Rs10.10 | Rs154.36 | x |
| 2006-03-31 | Rs13.48 | Rs154.36 | x |
| 2007-03-31 | Rs23.64 | Rs154.36 | x |
| 2008-03-31 | Rs15.04 | Rs154.36 | x |
| 2009-03-31 | Rs26.79 | Rs154.36 | x |
| 2010-03-31 | Rs25.66 | Rs154.36 | x |
| 2011-03-31 | Rs31.07 | Rs154.36 | x |
| 2012-03-31 | Rs36.06 | Rs154.36 | x |
| 2013-03-31 | Rs36.43 | Rs154.36 | x |
| 2014-03-31 | Rs36.79 | Rs154.36 | x |
| 2015-03-31 | Rs38.11 | Rs154.36 | x |
| 2016-03-31 | Rs36.23 | Rs154.36 | x |
| 2017-03-31 | Rs23.31 | Rs154.36 | x |
| 2018-03-31 | Rs20.94 | Rs154.36 | x |
| 2019-03-31 | Rs8.06 | Rs154.36 | x |
| 2020-03-31 | Rs216.07 | Rs154.36 | x |
| 2021-03-31 | Rs23.97 | Rs154.36 | x |
| 2022-03-31 | Rs26.19 | Rs154.36 | x |
| 2023-03-31 | Rs31.05 | Rs154.36 | x |
| 2024-03-31 | Rs34.17 | Rs154.36 | x |
| 2025-03-31 | Rs35.79 | Rs154.36 | x |
| 2026-03-31 | Rs40.63 | Rs154.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bafna Pharmaceuticals Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.54%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.37%
- • Asset Turnover: 0.86x
- • Equity Multiplier: 1.83x
- Recent ROE (11.54%) is above the historical average (-2.90%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 21.11% | 3.55% | 1.50x | 3.96x | Rs4.73 Million |
| 2006 | 16.25% | 4.53% | 0.95x | 3.78x | Rs3.55 Million |
| 2007 | 10.60% | 2.60% | 0.69x | 5.91x | Rs545.89K |
| 2008 | 10.11% | 3.03% | 0.77x | 4.31x | Rs129.77K |
| 2009 | 2.77% | 2.26% | 0.61x | 2.02x | Rs-27.85 Million |
| 2010 | 6.05% | 3.30% | 0.89x | 2.05x | Rs-16.19 Million |
| 2011 | 6.18% | 3.31% | 0.75x | 2.50x | Rs-20.71 Million |
| 2012 | 2.88% | 1.43% | 0.59x | 3.43x | Rs-45.41 Million |
| 2013 | 5.87% | 2.25% | 0.67x | 3.86x | Rs-27.83 Million |
| 2014 | 2.04% | 0.76% | 0.79x | 3.42x | Rs-54.82 Million |
| 2015 | 8.61% | 6.32% | 0.49x | 2.78x | Rs-10.01 Million |
| 2016 | -24.29% | -16.44% | 0.44x | 3.33x | Rs-198.02 Million |
| 2017 | -44.74% | -29.38% | 0.36x | 4.18x | Rs-233.53 Million |
| 2018 | -44.13% | -35.48% | 0.34x | 3.65x | Rs-205.29 Million |
| 2019 | -99.02% | -43.25% | 0.37x | 6.27x | Rs-207.76 Million |
| 2020 | -3.67% | -4.42% | 0.60x | 1.40x | Rs-69.89 Million |
| 2021 | 10.26% | 8.18% | 0.82x | 1.52x | Rs1.50 Million |
| 2022 | 8.42% | 6.13% | 0.94x | 1.45x | Rs-9.80 Million |
| 2023 | 15.44% | 9.83% | 0.89x | 1.76x | Rs39.93 Million |
| 2024 | 9.09% | 4.82% | 1.03x | 1.83x | Rs-7.36 Million |
| 2025 | 4.90% | 2.85% | 0.95x | 1.81x | Rs-43.28 Million |
| 2026 | 11.54% | 7.37% | 0.86x | 1.83x | Rs14.85 Million |
Industry Comparison
This section compares Bafna Pharmaceuticals Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $41,118,163,484
- Average return on equity (ROE) among peers: 13.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bafna Pharmaceuticals Limited (BAFNAPH) | Rs1.00 Billion | 21.11% | 0.75x | $39.49 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $366.97 Million | 3.51% | 2.41x | $25.11 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.23 Billion | 12.93% | 2.27x | $365.36 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $2.31 Million | -8.08% | 0.08x | $645.54 Million |
| Abbott India Limited (ABBOTINDIA) | $2.31 Billion | 29.62% | 0.43x | $6.01 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $32.64 Billion | 21.83% | 0.24x | $4.15 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.23 Billion | 13.11% | 3.52x | $996.26 Million |
| Alkem Laboratories Limited (ALKEM) | $75.58 Billion | 20.97% | 0.52x | $6.95 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.09 Billion | 18.92% | 0.29x | $170.62 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $22.20 Billion | 18.58% | 0.77x | $1.59 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $268.52 Billion | 7.18% | 0.49x | $8.98 Billion |
About Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited is a subsidiary of SRJR Lifesciences … Read more